In short
- Forty-five patients starting esketamine nasal spray for depression in two clinics in France were followed over the first four weeks.
- 58% had at least one full mystical-type experience on the MEQ-30 questionnaire.
- The authors argue these experiences are more than “dissociative side effects” and may be part of how the treatment helps.
What the researchers did
Clinicians assessed patients at each of their twice-weekly sessions during the first phase of treatment, using depression scales and the MEQ-30, the same Mystical Experience Questionnaire used in psilocybin research and in our own retreats.
What they found
Almost half the patients responded to treatment, with symptoms improving after just two sessions. Mystical experiences were common but varied widely between people and from one session to the next. The questionnaire worked for esketamine much as it does for classic psychedelics, and the mystical experiences were associated with later improvement in depression.
Why it matters
Ketamine is often called “dissociative”, as if what people experience were a side effect to be put up with. This study suggests something more interesting: for many patients the sessions can feel meaningful, even sacred, and that may be part of how they help. It is one reason why, in our ketamine-assisted psychotherapy in Scotland with Eulas Clinics, we work with the experience rather than around it.
Keep in mind
This was a small observational study without a control group, released as a preprint. It cannot show that the mystical experiences caused the improvement.
Ketamine-assisted psychotherapy in Scotland
Psychotherapy with ketamine, offered with Eulas Clinics, for people with depression and related difficulties.
Find out more about Ketamine-Assisted Psychotherapy in ScotlandThis summary is for information only and is not medical advice. Psychedelics are controlled substances in many countries, including the UK.
You may also like
Mystical, Not Challenging, Experiences Linked to OCD Improvement
In a Yale trial of psilocybin for treatment-resistant OCD, stronger mystical experiences predicted lower symptoms one and 12 weeks later.
Monika Knitter · 18 September 2026
ResearchWhen Nothing Feels Good: Can Psilocybin Help Bring Back Joy?
A small trial tested psilocybin with psychological support for anhedonia, the loss of pleasure, in treatment-resistant depression. The results were mixed but hopeful.
Monika Knitter · 6 November 2026
ResearchLight, Renewal and Oneness: Inside the Mystical Experience
Pooling 15 controlled studies, researchers found that mystical oneness under psychedelics is closely tied to feelings of renewal and luminous light.
Dr Christoph Zwolan · 31 March 2026
